In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients.
If austerity-minded governments aren't willing to pay for new drugs, then his company may have to choose not to launch new products there, choosing on a country-by-country basis where to do so.
Novo Nordisk and its profit-growth plans hit a roadblock earlier this year when the FDA refused to approve its new diabetes drug, Tresiba, without a new safety study. But CEO Lars Sorensen thinks he has an alternate route through a new weight-loss indication for the already top-selling Victoza.
Novo Nordisk's plant in Kalundborg, Denmark, the company's largest, has been pumping out products for nearly 45 years. When Novo needs a new product, it upgrades some portion of the plant and starts anew. That is what it is doing again.
When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk, the world's largest insulin maker, focused on a rapidly growing treatment area with investors expecting more, more, more.
China and India may top the list of fastest-growing pharma markets, but Brazil is no slouch, either. Drugmakers are wheeling and dealing there at an increasingly faster pace, as companies like Merck and Reckitt Benckiser join old-timers like Sanofi and GlaxoSmithKline in beefing up there.
A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.
EvaluatePharma has an antidote to any starry-eyed thinking about new drug launches. According to EP Vantage's new state-of-the-industry report, many of last year's rollouts are already disappointments, at least compared with previous sales projections.
As new diabetes drug Tresiba inches its way toward approval, Novo Nordisk and rival Sanofi have put up dueling studies and generated dueling headlines. But their rivalry extends beyond those two headlining drugs, Bloomberg reports.
Novo Nordisk completed a Phase I trial of its oral insulin drug, adding Novo to a short list of companies in the running to have the first version of the diabetes pill on the U.S. market.